An auto-injector is a type of syringe equipped with a spring-loaded needle and pre-loaded with a specific drug dosage. When pressed against the body and pushed with a sliding motion, it releases and administers a precisely measured dose of the medication. Auto-injectors offer several benefits, including the reduction of needle-related phobias, disorders, and the risk of needle stick accidents, among other advantages. Auto-injectors find applications in self-administering epinephrine to prevent anaphylaxis, providing immediate relief to migraine sufferers, and assisting in various medical and emergency treatments. The increasing incidence of anaphylaxis is driving the growth of the auto-injectors market.

Global Autoinjectors Market was valued US$ 56.5 Bn in 2022 and is expected to reach ~US$ 410 Bn by 2032, growing at a CAGR of 22.1% during the forecast period 2023-2032.

Auto-injectors are increasingly favoured over traditional devices due to their ability to enhance drug delivery efficiency and accommodate new formulations. Advancements in technology within this product category are expected to drive market growth. For instance, AbbVie, Inc.'s Humira includes features such as a locking function and injection starts and end alerts, showcasing the potential of technological innovation in auto-injectors.

Auto-injectors offer a range of benefits, including the reduction of needle-related anxiety, a lower risk of needle stick injuries, consistent dose accuracy, and improved overall efficacy. Compared to manual injections, auto-injectors provide more controlled drug delivery. The choice of the injection site typically depends on the drug's characteristics, with intramuscular administration being common. Auto-injectors are also less painful than traditional syringes, contributing to their increasing demand. However, the availability of alternative forms such as oral tablets may pose a hindrance to market growth.

The introduction of innovative device functions is expected to further drive growth. For example, in September 2015, Bayer HealthCare launched an electronic auto-injector for the treatment of relapsing-remitting multiple sclerosis. This device offers precise drug dosages, promoting patient compliance and potentially reducing overall treatment costs. The SHL group offers a variety of auto-injectors designed to handle large volumes and high-viscosity drugs.

COVID -19 Impact on Autoinjectors Market

Since the onset of the COVID-19 virus outbreak in December 2019, the disease has rapidly spread to more than 100 countries worldwide. The World Health Organization officially declared it a public health emergency on January 30, 2020. COVID-19 has the potential to impact the economy in three primary ways: by directly affecting the production and demand for pharmaceuticals, by causing disruptions in distribution channels, and through its financial repercussions on businesses and financial markets.

Due to widespread lockdown measures, numerous countries, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, have encountered challenges related to the transportation of pharmaceuticals from one location to another. However, it's worth noting that the COVID-19 pandemic has had a positive influence on the global auto-injectors market, primarily due to the increased development of vaccines and treatments for COVID-19. For example, in May 2022, the European Medicines Agency (EMA) granted approval for Vaxzevria to be used as a third-dose booster in adults within the European Union (EU). Consequently, the growing approvals for vaccines are expected to drive demand for injectable drug delivery devices such as needles and syringes.

Factors Driving the Autoinjectors Market

Drivers

Benefits of autoinjectors in emergency medical care

Autoinjectors provide several benefits, including simplified administration and the rapid delivery of medication. Critical conditions such as anaphylactic shocks and opioid overdose require immediate medical intervention. Anaphylactic shocks often result from factors like food allergies, insect stings, or drug allergies and can have fatal consequences if not promptly treated. Epinephrine has consistently been the primary treatment for anaphylaxis. Epinephrine autoinjectors offer advantages such as portability, swift administration, and are particularly valuable for individuals with a history of anaphylactic shocks. Consequently, autoinjectors play a pivotal role in addressing conditions that necessitate urgent medical attention. These advantages provided by autoinjectors are anticipated to bolster market growth.

Growing prevalence of chronic diseases

Chronic diseases such as cancer, diabetes, and cardiovascular conditions represent a significant economic burden, accounting for approximately USD$ 4.1 trillion annually in the United States. These diseases are major contributors to disability and mortality, as reported by the Centers for Disease Control and Prevention (CDC). As of July 2022, six out of ten adults in the U.S. are living with at least one chronic condition, with four out of ten individuals managing two or more chronic illnesses. The World Health Organization (WHO) projects that by 2030, one out of every six people worldwide will be over the age of 60. The global population of individuals aged 60 and older is expected to reach approximately 2.1 billion by 2050, with a further 426 million individuals aged 80 or older between 2020 and 2050. This aging demographic is associated with a higher prevalence of chronic diseases, leading to an anticipated rise in conditions, thereby driving the demand for Autoinjectors solutions. Consequently, this factor is a key driver contributing to the CAGR of the Autoinjectors market.

Moreover, there has been an increasing adoption of cutting-edge hardware and software technologies, reflecting a shift towards the development of advanced healthcare infrastructure to deliver more effective healthcare services. These advanced systems leverage networked data-sharing capabilities and harness big data in healthcare to automate data management, support decision-making, and provide robust data analysis services. The promotion of tele-consultation services, particularly in emerging economies, by government initiatives has boosted interest in mobile health (mHealth) services as a complementary approach to achieving healthcare-related Millennium Development Goals.

The increasing incidence of anaphylaxis is a key factor contributing to the expansion of the autoinjectors market. Anaphylaxis is a severe and life-threatening allergic reaction triggered by various factors such as drugs, latex, food, and Hymenoptera stings. Adrenaline autoinjectors are commonly used to treat anaphylaxis. This condition is prevalent, with a reported occurrence rate of approximately 1 in every 1,000 cases, according to studies conducted by NICE (the National Institute for Health and Care Excellence). Additionally, research published in the European Journal of Allergy and Clinical Immunology in 2019 revealed significant global variations in the prevalence of anaphylaxis among children. For every 100,000 individuals annually, approximately 1 to 761 experience anaphylaxis, with 1 in 77 cases attributed to food-related causes.

Restraint

Alternative modes of drug delivery

Traditional injection methods have typically relied on syringes, which can be a painful means of drug delivery. Consequently, both healthcare practitioners and patients are increasingly exploring alternative administration routes, including oral, nasal, and topical methods. Furthermore, advancements in technology have paved the way for the development of needle-free injectors. Additionally, certain medical conditions, such as diabetes, rheumatoid arthritis, and growth hormone deficiency, necessitate frequent drug administration. The high frequency of injections in these conditions may lead to needle phobia among patients, further encouraging them to consider alternative drug administration methods.

Autoinjectors Market Segmentation 

By Usage

The usage segment of the global autoinjectors market comprise of reusable and disposable segment. These segments differentiate based on their design, functionality, and purpose within the broader market of self-injection devices. Reusable autoinjectors are designed for multiple uses, typically allowing a patient to administer several doses of medication before needing a refill or replacement. They often come with refillable cartridges or reservoirs that can be loaded with medication for repeated use. Disposable autoinjectors are designed for a single administration. Once the medication is used, the entire device is discarded. These are typically pre-filled with a specific dosage of medication and are disposed of after use.

By Technology

The autoinjectors market is categorized into two key segments based on their technology: manual and automatic autoinjectors. These segments differ in their method of delivering medication and in the user experience they offer. Manual autoinjectors require the user to trigger the injection by applying force or pressure manually. Typically, the user needs to press a button or plunge the device against the skin to release the medication. Automatic autoinjectors are designed to trigger and administer the injection automatically once the device is placed against the skin and a safety mechanism is activated. This is often done through a trigger or button, and the injection process is initiated without the need for additional force or pressure from the user.

By Therapy

The therapy segment of the global autoinjectors market comprise of rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis and others.

In 2022, the autoinjectors market has been categorized by therapy into segments including Rheumatoid Arthritis (RA), multiple sclerosis, anaphylaxis, diabetes, and others. The rheumatoid arthritis segment is anticipated to dominate the market in terms of revenue during the forecast period, primarily due to the rising prevalence of this disease. Rheumatoid arthritis represents the most common form of autoimmune arthritis, affecting approximately 1% of the global population. In the United States, about 1.3 million individuals are affected by RA, accounting for 0.6% to 1% of the population. According to the Arthritis Foundation (AF), the global prevalence of RA in developed countries ranges from 0.5% to 1%. Furthermore, a 2020 study reported RA prevalence across the Middle East and Africa, ranging from 0.06% to 3.4%. RA predominantly affects women, with approximately 75% of RA patients being female. Leading market players are also making substantial contributions to this field. For instance, on March 29, 2022, Nordic Pharma, a Sever Life Sciences company, officially submitted a New Drug Submission to Health Canada for Nordimet, a methotrexate auto-injector used in the treatment of active RA and symptomatic management of severe, refractory psoriasis in adults who do not respond adequately to other therapies.

The anaphylaxis segment is expected to capture a significant portion of the market's revenue during the forecast period, mainly due to a considerable number of anaphylactic incidents triggered by drugs, food, insect stings, and latex. For instance, anaphylaxis is responsible for up to 0.26% of all hospital admissions. Research indicates a global increase in anaphylactic hospitalizations across regions such as the UK, Europe, the United States, Australia, and New Zealand, both due to all-cause anaphylaxis and specific triggers. Both the United States and Australia have reported significant rises in mortality rates related to drug-induced allergies.

By Route of Administration

The segmentation of the autoinjectors market into subcutaneous and intramuscular categories is based on the different methods of delivering medications into the body, specifically regarding the depth and location of the injection site. Subcutaneous autoinjectors are designed to deliver medication into the layer of tissue directly beneath the skin. This layer is rich in blood vessels and allows for relatively rapid absorption of the injected medication. They are primarily used for medications that are well-absorbed through subcutaneous tissue. These injections are often at a shallower depth compared to intramuscular injections, making them suitable for individuals who may prefer a less invasive injection method. Intramuscular autoinjectors are designed to penetrate deeper, delivering medication directly into the muscle. This method allows for faster absorption and distribution of the medication into the bloodstream compared to subcutaneous injections. They are often used for medications that require deeper penetration to ensure efficient absorption. The depth of the injection and the muscle tissue target may vary based on the specific medication and its administration requirements. Vaccines, certain antibiotics, and other medications that require a rapid and more direct delivery into the bloodstream are typically administered via intramuscular injections.

By Volume

The segmentation of the autoinjectors market into more than 3mL and less than 3mL segments primarily refers to the capacity or volume of medication that the autoinjector device can hold or deliver in a single administration. These autoinjectors are designed to contain and deliver a higher volume of medication in a single injection, typically exceeding 3 milliliters. They are commonly used for medications that require larger doses or volumes for effective treatment. This includes certain biologics, specific medications for chronic conditions, and therapies that demand higher doses. These autoinjectors are designed to hold and administer smaller volumes of medication, typically less than 3 milliliters. They are commonly used for medications that require smaller, more precise doses. This can include many common injectable medications such as certain vaccines, insulin for diabetes, and various other therapies requiring smaller volumes.

By End User

The segmentation of the autoinjectors market into home care and hospitals/clinics segments revolves around the primary settings where these devices are utilized, reflecting the diverse environments in which patients receive medical treatment. Autoinjectors in the home care segment are designed for patients to self-administer medication in their own residences. This caters to individuals managing chronic conditions or requiring frequent injections as part of their treatment regimen. These autoinjectors are often designed for ease of use, enabling patients or their caregivers to comfortably and safely administer medication without the need for medical professionals. Autoinjectors used in hospitals and clinics are typically administered by healthcare professionals such as nurses, doctors, or trained medical staff. These settings often deal with a wide range of patients with diverse medical needs. In hospitals and clinics, autoinjectors are utilized in a controlled, supervised environment, ensuring the correct administration of medication and proper disposal of medical waste. For patients who require regular injections as part of chronic disease management, the ability to self-administer at home enhances their quality of life. Meanwhile, in hospitals and clinics, autoinjectors serve a broader range of patients and are administered by healthcare professionals in various medical scenarios.

By Regions

By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America.

The North American market is poised to capture the largest share of revenue throughout the forecast period. This can be attributed to ongoing technological advancements in medical devices, a growing population of individuals with diabetes and anaphylaxis, and favorable government policies. For example, on June 15, 2022, Jabil Healthcare introduced the Qfinity autoinjector technology, a reusable and modular platform for Subcutaneous (SC) self-administration, aimed at addressing the pharmaceutical industry's increasing focus on sustainable drug delivery. Additionally, the increasing demand for home healthcare equipment and the strong presence of key market players are expected to contribute to revenue growth in this region.

The European market is projected to experience steady revenue growth over the forecast period, driven by rising investments and the expansion of healthcare infrastructure. For instance, on March 16, 2022, Ipsen announced its investment in a new state-of-the-art electronic autoinjector for Somatuline Autogel/Somatuline Depot (lanreotide), with the aim of advancing patient care and enhancing the administration and injection process.

The Asia Pacific market is anticipated to register a rapid CAGR during the forecast period, driven by increased healthcare spending, a growing diabetic population, and the burgeoning medical tourism industry. For example, within the IDF South-East Asia (SEA) Region in 2021, there were 90 million individuals (aged 20-79) with diabetes, and this number is expected to rise in the coming years. This has led to a significant influx of autoinjector device manufacturers, who are expanding their presence in the Asia Pacific region through various means, including establishing sales offices and collaborating with local pharmaceutical companies.

Competitive Landscape of Autoinjectors Market

Prominent market players are allocating substantial resources to research and development endeavors aimed at diversifying their product portfolios, further fueling the growth of the autoinjectors market. These market participants are also implementing various strategic initiatives to expand their global presence, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaborations with other organizations. In the increasingly competitive and growing market landscape of autoinjectors, competitors must deliver cost-effective solutions to extend their reach and thrive.

A fundamental business strategy embraced by manufacturers within the global autoinjectors industry, with the objective of benefitting clients and expanding market share, involves local manufacturing to reduce operational expenses. In recent years, the autoinjectors industry has brought substantial advancements to the field of medicine. Key players in the Autoinjectors market include AbbVie Inc. Mylan N.V., Lily, Amgen Inc., Ypsomed Holding, BD, Owen Mumford Ltd., Consort Medical, Plc, SHL Medical AG, Johnson Medtech, LLC, Teva Pharmaceuticals USA, Inc., Antares Pharma, AstraZeneca, Union Medico Inc., Gerresheimer AG and Emergent among others.

Recent Developments in the Autoinjectors Market

• On October 17, 2022, Ypsomed announced the introduction of a new autoinjector platform designed for liquid pharmaceuticals with volumes ranging from 1.5 mL to 5.5 mL. This latest addition to the YpsoMate portfolio enables self-administration of higher-volume drugs, including those used in the treatment of conditions such as cancer and rare autoimmune diseases.
• In May 2022, Jabil Healthcare, a subsidiary of Jabil Inc., introduced the Qfinity autoinjector platform. It is a straightforward, reusable, and modular solution designed for self-administration of subcutaneous (SC) drugs, offered at a more affordable price compared to other options in the market.
• In May 2022, Stevanato Group S.p.A. entered into an exclusive agreement with Owen Mumford Ltd., a prominent medical device developer and manufacturer, for the distribution of the Aidaptus auto-injector.
• On September 21, 2021, Owen Mumford Pharmaceutical Services, a division of Owen Mumford, successfully concluded the development of its innovative Aidaptus auto-injector platform. Aidaptus was designed to address issues related to changes in medication composition or injected volume, thereby reducing risks associated with drug development and lifecycle management.

Table of Contents

1. Executive summary
2. MARKET INTRODUCTION
   • MARKET SCOPE
   • MARKET Definitions
3. research methodology
4. market outlook
   • Key Trends
   • GUIDELINES / REGULATIONS
   • COVID-19 IMPACT ON GLOBAL AUTOINJECTORS MARKET
   • MARKET DYNAMICS
     • Drivers
       • Benefits of autoinjectors in emergency medical care
       • Availability of generics and biosimilars in autoinjectors
       • Growing awareness and adoption of self-administration
       • Rising incidence of chronic and lifestyle diseases
     • Restraints
       • Availability of alternative drug delivery systems
     • Opportunities
       • Increasing regulatory approvals for autoinjectors
     • Challenges
       • Stringent regulatory compliance
     • PriCing Analysis
     • PORTER’S FIVE FORCE MODEL
       • Threat of new entrants
       • Threat of substitute
       • Bargaining power of suppliers
       • Bargaining power of buyers
       • Intensity of competitive rivalry

5. GLOBAL AUTOINJECTORS MARKET, By usage, MARKET ESTIMATION AND FORECAST, 2022-2032), value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • Reusable
   • disposable
6. GLOBAL AUTOINJECTORS MARKET, By technology, MARKET ESTIMATION AND FORECAST, 2022-2032), value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • manual
   • automatic
7. GLOBAL AUTOINJECTORS MARKET, BY therapy, MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • rheumatoid arthritis
   • multiple sclerosis
   • diabetes
   • anaphylaxis
   • others
8. GLOBAL AUTOINJECTORS MARKET, BY route of administration, MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • Subcutaneous
   • Intramuscular
9. GLOBAL AUTOINJECTORS MARKET, BY Volume, MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • More than 3ML
   • Less than 3ML
10. GLOBAL AUTOINJECTORS MARKET, BY End user, MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)
    • INTRODUCTION
    • MARKET SHARE ANALYSIS
    • home care
    • hospitals and clinics
11. GLOBAL AUTOINJECTORS MARKET, REGIONAL ANALYSIS MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)
    • INTRODUCTION
    • NORTH AMERICA AUTOINJECTORS MARKET
      • North America Autoinjectors Market, By Country
        • US
        • Canada
        • Mexico
      • North America Autoinjectors Market, By Usage
      • North America Autoinjectors Market, By Technology
      • North America Autoinjectors Market, By Therapy
      • North America Autoinjectors Market, By Route of Administration
      • North America Autoinjectors Market, By Volume
      • North America Autoinjectors Market, By End User
    • EUROPE AUTOINJECTORS MARKET
      • Europe Autoinjectors Market, By Country
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
      • Europe Autoinjectors Market, By Usage
      • Europe Autoinjectors Market, By Technology
      • Europe Autoinjectors Market, By Therapy
      • Europe Autoinjectors Market, By Route of Administration
      • Europe Autoinjectors Market, By Volume
      • Europe Autoinjectors Market, By End User
    • ASIA PACIFIC AUTOINJECTORS MARKET
      • Asia Pacific Autoinjectors Market, By Country
        • China
        • Japan
        • India
        • Australia
        • Singapore
        • South Korea
        • Thailand
        • Indonesia
        • Malaysia
        • Philippines
        • Rest of Asia Pacific
      • Asia Pacific Autoinjectors Market, By Usage
      • Asia Pacific Autoinjectors Market, By Technology
      • Asia Pacific Autoinjectors Market, By Therapy
      • Asia Pacific Autoinjectors Market, By Route of Administration
      • Asia Pacific Autoinjectors Market, By Volume
      • Asia Pacific Autoinjectors Market, By End User
    • MIDDLE EAST & AFRICA AUTOINJECTORS MARKET
      • Middle East & Africa Autoinjectors Market, By Country
        • UAE
        • Saudi Arabia
        • South Africa
        • Rest of Middle East & Africa
      • Middle East & Africa Autoinjectors Market, By Usage
      • Middle East & Africa Autoinjectors Market, By Technology
      • Middle East & Africa Autoinjectors Market, By Therapy
      • Middle East & Africa Autoinjectors Market, By Route of Administration
      • Middle East & Africa Autoinjectors Market, By Volume
      • Middle East & Africa Autoinjectors Market, By End User
    • SOUTH AMERICA AUTOINJECTORS MARKET
      • South America Autoinjectors Market, By Country
        • Brazil
        • Argentina
        • Peru
        • Rest of South America
      • South America Autoinjectors Market, By Usage
      • South America Autoinjectors Market, By Technology
      • South America Autoinjectors Market, By Therapy
      • South America Autoinjectors Market, By Route of Administration
      • South America Autoinjectors Market, By Volume
      • South America Autoinjectors Market, By End User

12. GLOBAL AUTOINJECTORS MARKET, COMPETITIVE Intelligence
    • COMPETITIVE POSITIONING
    • competitor benchmarking
    • Competitive Quadrant
    • market share analysis, 2022 (%)
13. GLOBAL AUTOINJECTORS MARKET, COMPANY ANALYSIS
    • AbbVie Inc.
      • Company Overview
        • Business outlook
        • Headquarter
        • Established/Incorporated
        • Headcounts/ Employee strength
      • Financial Overview
        • Sales/revenue
        • R&D expenditure
        • Business segment sales share
        • Regional sales share
      • Product Offerings
      • SWOT Analysis
      • Key Developments (Expansion/New Product Development/Agreement/Mergers & Acquisitions, Partnership/Investment/Etc.)
    • Amgen Inc.
    • Antares Pharma, Inc.
    • Becton, Dickinson and Company (BD)
    • Biogen
    • Elcam Drug Delivery Devices (E3D)
    • Eli Lilly and Company
    • Gerreshiemer AG
    • Haselmeier GmbH
    • Jabil, Inc.
    • Merck KGaA
    • Novartis AG
    • Oval Medical Technologies Ltd.
    • Owen Mumford Ltd.
    • Philip-Medisize, LLC
    • Recipharm AB
    • SHL Medical
    • Solteam Incorporation Co., Ltd.
    • Viatris Inc.
    • West Pharmaceutical Services, Inc.
    • Ypsomed Holding AG
    • OTHERS

*Financials and Details May Not be Included in Case of Privately Held Company

Global Auto injectors Market Segmentation

Auto injectors by Type: Market Size & Forecast 2023-2030

• Pen injectors
• Prefilled syringes
• On-body injectors
• Reusable injectors
• Disposable injectors

Auto injectors by Application: Market Size & Forecast 2023-2030

• Chronic diseases
• Emergency situations
• Vaccinations
• Self-administration of medications
• Hospital use
• Home use

Auto injectors by User: Market Size & Forecast 2023-2030

• Patients
• Healthcare professionals
• Veterinarians

Auto injectors by Distribution Channel: Market Size & Forecast 2023-2030

• Hospitals
• Pharmacies
• Online retailers
• Direct-to-patient sales

Auto injectors by Technology: Market Size & Forecast 2023-2030

• Spring-powered
• Gas-powered
• Electronic
• Connected devices

Auto injectors by Geography: Market Size & Forecast 2023-2030

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

• AbbVie Inc.
• Amgen Inc.
• Eli Lilly and Company
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Becton, Dickinson and Company (BD)
• Mylan N.V.
• Pfizer Inc.
• Novartis AG
• Ypsomed AG
• Antares Pharma, Inc.
• SHL Medical AG
• Bespak Europe Ltd.
• Gerresheimer AG
• Consort Medical plc
• Oval Medical Technologies Ltd. (a SMC Ltd. Company)
• Elcam Medical
• Haselmeier AG
• Owen Mumford Ltd.
• Enable Injections
• West Pharmaceutical Services, Inc.
• Sensile Medical AG
• Biogen Inc.
• Kaleo, Inc.
• Sorrel Medical